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Abstract  
Objective : Orexins are neuropeptides involved in energy homeostasis. We 
investigated the effect of orexin A (OxA) and OxB on intestinal glucose transport in 
the rat. Research Design and Methods : Injection of orexins led to a decrease in the 
blood glucose level in OGTT. Effects of orexins on glucose entry were analysed in 
Ussing chamber using the Na+-dependent increase in short-circuit current to 
quantify jejunal glucose transport. Results & Conclusions : The rapid and marked 
increase in Isc induced by luminal glucose was inhibited by 10 nmol/l OxA or OxB 
(53 and 59% respectively). Response’ curves to OxA and OxB were not significantly 
different with IC50 at 0.9 and 0.4 nmol/l, respectively. On the one hand, OxA-
induced inhibition of Isc was reduced by the neuronal blocker TTX, and by a CCK2R 
antagonist, indicating involvement of neuronal and endocrine CCK-releasing cells. 
The OX1R antagonist SB334867 had no effect on OxA-induced inhibition, which is 
likely to occur via a neuronal and/or endocrine OX2R. On the other hand, SB334867 
induced a significant right shift of the concentration-effect curve for OxB. This OxB-
preferring OX1R pathway was not sensitive to TTX or to CCKR antagonists, 
suggesting that OxB may act directly on enterocytic OX1R. These distinct effects of 
OxA and OxB are consistent with the expression of OX1R and OX2R mRNA in the 
epithelial and non-epithelial tissues, respectively. Our data delineate a new function 
for orexins as inhibitors of intestinal glucose absorption and provide a new basis for 
orexin-induced short-term control of energy homeostasis. 
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Orexins/hypocretins are peptides discovered by orphan receptor technologies (1) or 
subtractive cDNA cloning (2). The two orexins, A and B, are encoded by a single 
gene and are derived from a common prepro-orexin that is processed into the 33-
amino acid orexin-A (OxA) and the 28-amino acid OxB. These peptides share 46% 
amino acid identity in rat (3). Orexins are neuropeptides present in the hypothalamic 
neurons that project throughout the central nervous system (CNS) to nuclei involved 
in the control of feeding, sleep-wakefulness, neuroendocrine homeostasis and 
autonomic regulation (1; 3). Two orexin receptor subtypes, OX1R and OX2R (1; 2), are 
serpentine G protein-coupled receptors that bind both orexins. As shown in rat, 
OX2R binds OxA and OxB with equal affinity whereas OX1R has a preference for OxA (1; 
3). Both receptors appear to be coupled to calcium mobilisation (1; 3). As with other 
peptides found in the hypothalamic area (ie. PYY, NPY, leptin, ghrelin, galanin) 
belonging to the so-called brain-gut axis, expression of orexins has also been reported 
in enteric neurons and endocrine cells of the digestive tract (4; 5). OxA was 
demonstrated to trigger cholecystokinin (CCK) release in STC-1 cells, an intestinal 
neuroendocrine cell model that expresses OX1R and OX2R (6). These studies, together 
with those characterising the orexin receptors in the enteric nervous system, pancreas 
and intestinal mucosa cells (4; 5; 7), suggest that orexins can exert direct control on 
gut functions.  
The hypothalamus has been the focus of considerable attention regarding its role in 
the regulation of energy homeostasis, but the gut is now also considered as a major 
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player in the regulation of food intake. To achieve energy homeostasis, the CNS 
integrates signals coming from the peripheral organs that provide information about 
the level of energy fluxes and stores through neuronal pathways. Primary input is 
mediated by signal molecules conveyed in the intestinal lumen. Glucose, the major 
form of absorbed carbohydrate, is also an important signal molecule. Glucose levels 
in the bloodstream are critically evaluated by integrated hypothalamic circuits of 
neurons and neurochemicals that regulate appetite, energy expenditure and 
metabolism. Orexin neurons have been recently identified to play a major role in this 
regulation (8-10). Orexin glucosensing neurons can modulate their intrinsic electrical 
activity according to the ambient fluctuations in the levels of nutrients and appetite-
regulating hormones, and are believed to translate directly rises and falls in body 
energy levels into different states of consciousness (10).  
Following a meal, exogenous glucose is rapidly transported from the lumen of the 
small intestine into the blood stream and tissues. The first step of this process is the 
intracellular accumulation of glucose in enterocytes by the sodium-dependent 
glucose transporter 1, SGLT1. Intracellular glucose is then released into the 
interstitial space and blood via the GLUT2 glucose transporter located in the 
basolateral membrane. The activity of SGLT1 is highly regulated by hormones and 
intestinal peptides (11-15) indicating that control of intestinal glucose entry is crucial 
in the maintenance of energy homeostasis. Indeed, expression of SGLT1 is 
dramatically increased in diabetic humans (16). Although orexins and their receptors 
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have been found in the gastrointestinal tract, their role in the regulation of intestinal 
glucose transport has not yet been studied.  
 
The present study was conducted to determine whether orexins A and B modulate 
intestinal glucose transport. We demonstrate a new physiological role for both OxA 
and OxB in the inhibitory control of intestinal glucose absorption and we describe 
distinct cellular pathways for their action that allow OX1R and OX2R to be 
distinguished.  
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Research Design and Methods 
Animals. Male Wistar rats weighing 240–280 g (Centre Elevage Janvier, Le Genest-St-
Isle, France) were caged under standard laboratory conditions with tap water and 
regular food provided ad libitum, in a 12-h/12-h light/dark cycle at a temperature of 
21–23°C. The animals were treated in accordance with European Community 
guidelines concerning the care and use of laboratory animals. 
Oral glucose tolerance test. Oral glucose tolerance test (OGTT) was performed on 
conscious rats, following a 18 h fasting. Blood samples from fasted animals were first 
taken from the tail vein by 10:00 o’clock in the morning. OxA or OxB (55 µg/kg) 
diluted in NaCl 0.9% were administered by i.p. route five min before the OGTT. 
Controls received vehicle only. Rats in all groups were fed a 30% D-glucose solution 
(1 g/kg body weight) and blood samples taken by tail bleeds at 15, 30, 60 and 120 min 
after glucose administration. Glucose determination in blood was run immediately 
using an Accu-Chek Go (Roche Diagnostics, Meylan, France). Area under the curves 
were calculated according to the trapeze method and expressed in arbitrary units. 
Tissue preparation and short-circuit measurement. Rats were fasted 16 h with water 
ad libitum. Animals were killed by i.p. pentobarbital overdose and the proximal 
jejunum was dissected out and rinsed in cold saline solution. The mesenteric border 
was carefully stripped off and the intestine was opened along the mesenteric border. 
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Four adjacent proximal samples were mounted in Ussing chambers as described (11). 
The tissues were bathed on each side with carbogen-gassed Krebs-Ringer bicarbonate 
(KRB) solution having the following composition (in mmol/l) : NaCl 115.4, KCl 5, 
MgCl2 1.2, NaH2PO4 0.6, NaHCO3 25, CaCl2 1.2 and glucose 10. In the solution 
bathing the mucosal side of the tissue, glucose was replaced with mannitol. Mannitol 
was kept in the bathing solution during glucose challenge. Both solutions were 
gassed with 95% O2-5% CO2 and kept at constant temperature of 37°C (pH at 7.4). 
Electrogenic ion transport was monitored continuously as short-circuit current (Isc) 
using an automated voltage clamp apparatus (DVC 1000, WPI, Aston, England) 
linked through a MacLab 8 to a MacIntosh computer. Orexins were added in the 
serosal bath 2 min before luminal glucose challenge. Results were expressed as the 
difference (OIsc) between the peak Isc after glucose challenge (maximum measured 
after 3 min) and the basal Isc (measured just before the addition of glucose). 
Response’ curves to orexins were studied non-cumulatively. OIsc response to 
carbachol (100 µmol/l) was used at the end of the experiment as a control. 
Epithelial cell isolation and RT-PCR analysis 
Epithelial and non epithelial cellular fractions of rat jejunum were obtained from 
everted jejunum shaken in a dispersing solution containing EDTA as described in 
detail previously (17; 18). Non-epithelial tissues were obtained after complete 
removal of epithelial cells. 
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Total RNA was extracted from cultured cell lines (CHO/ OX1R or CHO/ OX2R) or 
from intestinal cells using Trizol® reagent (Invitrogen, Cergy-Pontoise, France). All 
RNA preparations were treated with RNAse free-DNAse (Promega, Charbonnières, 
France) for 60 min at 37°C. Five µg of RNAt were reverse transcribed using oligo(dT) 
primers. Twenty-five percent of the cDNA mixture were amplified using human 
OX1R sense primer (5’-CCTGTGCCTCCAGACTATGA-3’) and OX1R antisense 
primer (5’-ACACTGCTGACATTCCATGA-3’) or OX2R sense primer 
(5’TAGTTCCTCAGCTGCCTATC-3’) and OX2R anti-sense primer 
(5’CGTCCTCATGTGGTGGTTCT-3’) or GADPH sense primer 
(5’TGAAGGTCGGAGTCAACGGATTTGGT-3’) and GADPH anti-sense primer 
(5’CATGTGGGCCATGAGGTCACACAC-3’). Each of the 35 cycles of amplification 
consisted of 94°C for 1 min, 62°C for 1 min and 72°C for 1 min. Amplicons were 
separated by electrophoresis in 1% agarose gels, stained with ethidium bromide and 
viewed under UV illumination. 
Chemicals. Orexins A and B were purchased from R&D Systems (R&D Systems 
Europe Ltd, Abingdon, United Kingdom). Tetrodotoxin (TTX) was purchased from 
Alomone labs (Alomone Labs Ltd, Jerusalem, Israel). SB334867, an OX1R specific 
antagonist, was purchased from Tocris Bioscience, (Bristol UK).  Antagonists and 
TTX were added in serosal bath 10 min before orexins. Ala11,D-Leu15OxB, an OX2R
specific agonist, was purchased from Calbiochem (La Jolla, CA). All other chemical 
reagents were purchased from Sigma (St. Louis, MO, USA). 
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Statistical Analysis. All results were expressed as means ± SEM with n = number of 
tissues. One-way ANOVA with Tukey-Kramer multiple comparison post test was 
performed using GraphPad Prism version 3.0 for Windows (Graphpad software Inc., 
San Diego, CA). The level of significance was set at P<0.05. 
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Results 
 
Oral glucose tolerance test. To evaluate the impact of peripheral OxA and OxB on 
glucose homeostasis, we performed oral glucose tolerance tests (OGTT) on conscious 
rats after i.p. administration of OxA or OxB (55 µg/kg). As depicted in Fig. 1, blood 
glucose concentration following glucose feeding was significantly reduced in rats 
receiving i.p. injection of OxA. Blood glucose level at 15 min was not significantly 
different from those in controls but glycemia was markedly decreased at 30 (P<0.008) 
and 60 (P<0.012) min. With OxB, blood glucose level was also decreased but it 
reached statistical significance fo  15 min only (Fig. 1). Areas under the curve (AUC) 
were significantly decreased for both OxA and OxB as compared to control (Fig. 1, 
inset). Altogether, these data indicate that peripherally administered OxA and OxB 
can reduce intestinal absorption of glucose in a glucose tolerance test. When glucose 
is given luminally, the OGTT is an index of intestinal glucose entry through the 
glucose transporter SGLT-1 (19). Therefore, we further examined in vitro the effect of 
orexins on active intestinal absorption of glucose.  
 
Intestinal glucose transport in vitro is inhibited by OxA and OxB. Luminal addition 
of 10 mmol/l glucose to the jejunal preparation (control) induced a rapid and marked 
increase in Isc (vs basal condition before glucose challenge; Fig. 2A) which plateaued 
at 3 min : OIsc = 27.0 ± 2.3 µA/cm2 , n=20. Serosal addition of OxA or OxB (10 nmol/l), 
two minutes before glucose challenge, significantly decreased glucose-induced Isc, 
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with Isc values at plateau of 11.6 ± 3.9 µA/cm2 (n= 5) and 13.3 ± 2.5 µA/cm2 (n= 8), 
for OxA and B respectively (57 and 50.7% inhibition respectively). We then studied 
dose-effect of OxA and OxB. As shown in Figure 2B, maximal effects of OxA and 
OxB were observed at 100 nmol/l peptide concentration and represented a ~70% 
inhibition of glucose-induced Isc. The IC50 values for OxA and OxB were 0.9 and 0.4 
nmol/l, respectively. To analyse the pathways involved in this inhibition, we 
examined the effect of the OX1R antagonist SB334867. The response to OxA was not 
significantly modified by SB334867 (Fig. 3A). In sharp contrast, the Ox1R antagonist 
markedly shifted to the right the dose-response curve to OxB (Fig. 3B). This clearly 
indicates that the effect of OxB involves an OX1 receptor whereas the effect of OxA is 
mostly independent of the OX1 receptor. In the absence of available OX2R antagonist, 
we could not further explore the orexin receptor mediating the effect of OxA. 
 
Analysis of the pathway involved in the inhibitory action of OxB on glucose-
induced Isc. Recent morphological data showed that OX1R immunoreactivity is 
present in the gut in neuronal cell bodies and mucosal epithelial cells, including 
enteroendocrine cells and enterocytes (5). We first examined the effect of the 
neuroblocker tetrodotoxin (TTX, 5 µM) on OxB-mediated inhibition of glucose-
induced Isc. As shown in Fig 4A, TTX had no effect on OxB-induced inhibition, 
indicating that neuronal cells do not play a significant role in this effect. We then 
examined the possible relay of endocrine cells in the action of OxB. We focused our 
attention to endocrine I cells for three reasons: i) CCK-producing I cells are present in 
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the vicinity of epithelial cells in duodenum and proximal small intestine (20); ii) 
endocrine I cells release CCK in response to different stimuli, including orexins (6);  
iii) CCK is an inhibitor of SGLT1 and subsequently an inhibitor of glucose absorption 
(12). In order to explore the possible involvement of endocrine I cells and CCK in the 
response to OxB, we tested the effects of a mixture of CCK1R and CCK2R antagonists 
in our Ussing chamber model. As shown in Fig 4B, CCKR antagonists did not modify 
the effect of OxB on glucose-induced Isc. These data clearly indicate that OxB does 
not target enteric neurons or endocrine I cells for inhibiting glucose absorption. 
Therefore, our hypothesis is that OxB inhibits glucose absorption through direct 
interaction with OX1R on enterocytes.  
 
Analysis of the pathway involved in the inhibitory action of OxA on glucose-
induced Isc. We first examined the effect of the neuronal blocker TTX on OxA action. 
As shown in Fig. 4C, dose-effect curve for OxA was markedly shifted to the right in 
the presence of TTX. However, for high concentrations of OxA, TTX only partially 
blocked the effect of OxA, suggesting the existence of a TTX-insensitive component 
in OxA action.   
The TTX-resistent effect of OxA could be due to the activation of the OX1R identified 
in enterocytes (see above). We therefore ran additional experiments in which the 
effect of 100 nmol/l OxA in the presence of TTX was determined with or without the 
OX1R antagonist SB334867. Our data clearly indicated that the OX1R antagonist 
completely blocked the TTX-insensitive component in the action of OxA : control 24.3 
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± 1.7 µA/cm2 (n= 4); OxA 100 nmol/L alone : 8.0 ± 0.8 µA/cm2 (n= 4); OxA 100 nmol/L 
plus TTX: 17.0 ± 4.1 µA/cm2 (n= 3); OxA 100 nmol/L plus TTX plus SB334867: 28.3 ± 
4.4 µA/cm2 (n= 3). 
The TTX-sensitive component of OxA plays a major role in its inhibitory effect on 
glucose absorption. The neurochemistry of neurons involved in the action of OxA 
remains unclear since no information is currently available regarding the expression 
of orexin receptors in mucosa while OX1R is reported in myenteric plexus . However, 
the fact that OxA was shown previously to increase CCK release (6), prompted us to 
investigate the role of CCK receptor antagonists on OxA action. As shown in Fig 4D, 
the inhibition of glucose transport induced by OxA was reduced by a mixture of both 
CCK1R and CCK2R antagonists. To gain further insight into the subtype of CCK 
receptor involved in this pathway, we set out to determine the sensitivity of a single 
concentration of 10 nmol/l OxA, which is close to IC50, in presence of either 
antagonists. As shown in Fig 5, the inhibition of glucose transport induced by 10 
nmol/l OxA was completely abolished by the CCK2R antagonist YM022 (1 nmol/l), 
but not by the CCK1R antagonist L-364718. These data indicate that the OxA effect 
on intestinal glucose absorption involves a CCK2R. Since this major component of 
OxA action is not mediated by the OX1R (see Fig. 3A), it is likely that it involves the 
other orexin receptor, i.e. OX2R. This is in agreement with our finding that a specific 
OX2R agonist triggers an inhibition of glucose absorption (Fig. 6). In line with the 
effect of TTX on OxA-induced inhibition, the effect of the OX2R agonist was sensitive 
to TTX. Also in accordance with the involvement of CCK2R in this pathway, 
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inhibition induced by OX2R agonist was found sensitive to CCK2R antagonist YM022 
(Fig.6). 
 
Analysis of OXRs mRNA distribution in jejunal mucosa 
Finally, RT-PCR analysis of OxRs in rat jejunal mucosa showed the expression of 
OX1R in epithelial cells (Fig 7; lane 5) but not in non-epithelial fraction (Fig 7; lane 7), 
in line with our functional results. In contrast, OX2R was found essentially in non-
epithelial fraction (Fig 7; lane 7), a localization in good agreement with the expression 
of OX2R in neurons. A small amplicon was also found in the epithelial fraction, 
possibly corresponding to the presence of OX2R in enteroendocrine cells (Fig 7; lane 
5). 
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Discussion 
Our results demonstrate that OxA and OxB acutely inhibit the active absorption of 
luminal glucose mediated by SGLT-1. This delineates a new function for orexins in 
the short-term control of enterocyte glucose absorption and provides an original 
insight into the role of orexins as a link between peripheral energy balance and the 
CNS (21; 22). As glucose is both an energy-rich molecule and a signal molecule, the 
initial arrival of glucose in the intestinal lumen and its absorption into enterocytes 
through SGLT-1 is a major event in the energy homeostasis process. The nature of the 
peripheral neural circuitry through which homeostatic pathways may be integrated 
into the regulation of energy balance, appetite, locomotor control and body weight is 
not yet fully understood. Many recent studies have shown that orexin neurons are 
sensitive to changes in nutritional status. In normal mice, orexin expression 
negatively correlates with changes in blood glucose (23). Fasting or insulin-induced 
hypoglycemia upregulates rat prepro-orexin (1) and orexin mRNA (24) and 
stimulates c-Fos expression in orexin neurons (25), indicating that changes in 
circulating glucose concentration can activate orexin neurons. OxA secretion from 
the endocrine pancreas is also stimulated by low glucose levels (7). Our finding that 
orexin A and B can induce a short-term modulation of the incoming flux of glucose 
gives a new insight into the involvement of orexins in glucose regulation. 
We found that both orexins reduced significantly blood glucose when administered 
by i.p. route. In previous studies, it was found that OxA, when given I.V.,  had no 
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effect on glycemia (5) or increased it (7). Whether difference in the dose delivered 
and/or in the route of administration (i.p. vs. I.V.) is concerned remains to be 
determined.  
Uptake of alimentary glucose by SGLT1 is a fundamental process that is regulated by 
several hormones and peptides. These peptides can lead to a decrease (i.e. leptin (11; 
26), CCK (12) or an increase (i.e. adenosine (27), EGF (13), GLP-2 (14), GIP (28) or 
insulin (15)) in glucose transport.  The activity of SGLT-1 and the resulting glycaemia 
occur in the context of a balance between the activating and inhibitory hormones, 
peptides and neuropeptides that modulate the activity of the glucose transporter 
according to food availability. The relevance of the effect of endogenous orexins on 
glycemia should be considered in this physiological context. This should explain why 
orexin knockout mice exhibit normal blood glucose (29).  
Another important finding is the distinct mode of action of orexins A and B on 
enterocyte function. Such marked differences in the mechanism of action of orexin 
peptides have not been reported previously. Indeed, either OxA or OxB were found 
to be active in vivo and in vitro with IC50 values in the low nanomolar range and 
significant activities still being observed in the pM range. In this context, we were 
able to dissect the pathways involved in orexins actions leading to propose a novel 
scheme to illustrate how endogenous OxA and OxB inhibits SGLT1-mediated 
glucose absorption across enterocytes (Figure 8). We found that OxA was sensitive to 
TTX (indicating the involvement of neuronal cells) and also sensitive to the CCK2R 
antagonist (indicating the involvement of endocrine I cells). These results may be 
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explained by several potential mechanisms. First, neurosecretion of OxA could 
activate OX2R present on as yet uncharacterized neuronal cell types which, in turn, 
release an unknown neurotransmitter to activate neuroendocrine I cells to secrete 
CCK (Figure 8; pathway 1). The nature of the neuronal cells involved in this pathway 
is unknown and requires further investigation. Second, OxA could directly activate 
endocrine I cells via OX2R (Figure 8;  pathway 2). This is consistent with a previous 
report on neuroendocrine STC-1 cells, which express OX2R and release CCK in 
response to orexin A (6).  Third, OxA could also directly activate efferent CCK-
releasing neuronal cells via OX2R (Figure 8; pathway 3). Such efferent CCK cells have 
been described in submucosal networks of enteric neurons (30). In our scheme, these 
pathways are not mutually exclusive. In all cases, CCK released by endocrine I cells 
is certainly a major mediator of OxA action in the inhibition of SGLT-1 activity. 
However, the fact that the action of OxA is not completely inhibited by the CCKR 
antagonist cocktail (Fig. 4C) suggests the possible involvement of minor mediators in 
this action, the nature of which remains to be established. Here, we further 
demonstrate that this CCK-mediated effect of OxA involved a CCK2R subtype. This 
finding is in agreement with previous data showing that inhibition by leptin of 
glucose absorption in rat jejunum is mediated by CCK (11).  
Conversely, our data indicate that OxB produced and secreted by neuronal cells in 
the mucosa could directly activate the OX1R on enterocytes (Figure 8; pathway 4). 
Indeed, we found that OxB–induced inhibition was not sensitive to TTX, indicating 
the absence of a neuronal intermediate between the local release of neuropeptide and 
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its action on epithelial cells. As STC-1 cells have been shown to express both types of 
orexin receptors, it is conceivable that these cells may also be responsive to OxB. The 
absence of significant modifications in the effect of OxB in the presence of CCKR 
antagonists (Figure 4B) indicates that this effect does not involve CCK-releasing cells 
but rather suggests that it is a direct effect on enterocytes. The inhibitory effect of 
OxB appears to be mediated by OX1R, as indicated by the sensitivity of the OxB effect 
to the OX1R antagonist SB334867 (Fig. 3B). Analysis of OxR transcripts in the 
epithelial and non-epithelial compartments of mucosa gave results that were 
consistent with this global scheme. Indeed, OX1R was found only in the epithelial 
fraction that corresponds to enterocytes. In contrast, OX2R expression was found 
mainly in the non-epithelial fraction of the mucosa containing neuronal cells, with 
also a small signal in epithelial fraction that may be ascribed to the presence of 
endocrine cells within the jejunal epithelium. Another analysis of OXR distribution in 
the gut by RT-PCR showed the expression of OX1R mRNA in submucosal and 
myenteric plexus of the guinea-pig duodenum and rat ileum (31). Whether this 
discrepancy is related to difference in species or organ distribution remains to be 
determined. 
The nature of the peripheral neural circuitry through which signals from the 
homeostatic pathways may be integrated into the regulation of energy balance, 
appetite, locomotor control and body weight is not yet fully understood. Orexin 
neurons have been recently demonstrated to sense blood glucose levels in both 
central and peripheral areas (10). Our finding that orexins have a peripheral effect on 
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glucose entry and its consequences on glucose level in vivo suggests a possible link 
between intestinal entry of glucose and orexin glucosensing neurons in the 
submucosal plexus that may respond to and integrate signals involved in the 
regulation of energy homeostasis, resulting in negative feedback and adjustment of 
energy levels. In line with their recently demonstrated role in glucose sensing in the 
CNS, orexins appear to be important players in the physiological regulation of 
peripheral glucose levels. Orexins have been shown to be involved in the central 
regulation of wakefullness and locomotor activity that support food seeking. There 
are increasing data to support the concept that reduced food availability has a global 
stimulatory effect on reward perception (32). By decreasing neuronal input from 
adiposity signals, energy restriction increases responses to rewarding stimuli. A 
model has been proposed in which peripheral signals reflecting negative energy 
balance, such as reduced plasma glucose, induce fasting-related arousal by triggering 
increased activity of orexin neurons (23). We propose that orexins released by 
neurons and endocrine cells in the gut, and acting via distinct pathways, are 
connected to glucose transporter activity to allow sensing and control of incoming 
levels of glucose (as a part of a glucose “sensing” cell network that includes the 
pancreatic cells (7) and duodenal SGLT-3 sensing (33)). Modulation of glucose levels 
through this postulated loop, in close relationship with other hormones and 
neuropeptides (i.e. leptin, CCK, ghrelin), could in turn result in an increase in 
neuronal activity (32) and in production/secretion of peripheral orexin (7).  
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In conclusion, our data provide a rational basis for orexin-induced short-term 
regulation of intestinal glucose transport. Together with the recent findings that 
orexin neurons are specialised cells for sensing blood glucose in the hypothalamus 
(10), our results indicate that orexins can also modulate peripheral glucose disposal. 
In addition, they suggest that orexins are also involved in a regulatory loop between 
enteric glucose entry and central evaluation of peripheral available energy levels, 
enlarging the group of gut peptides involved in energy homeostasis (34). Further 
studies are needed to evaluate this possible role of orexins in pathologies associated 
with anomalies in energy homeostasis including obesity and diabetes. 
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Legends to Figures 
Figure 1. Oral glucose tolerance test (1 g/kg) in rats. Rats were injected i.p. with 
saline (control, ), or with 55 µg/kg OxA (X) or OxB () five min before they were 
challenged by oral administration of a 30% D-glucose solution. Results are presented 
as mean ± SEM. n= 6-10. *P<0.05. Area under the curve (insert) is expressed in 
arbitrary units (AU). 
 
Figure 2. Effect of OxA and OxB on glucose-induced short-circuit current (Isc). A. 
Typical recording of Isc (in µA/cm2) across rat jejunum mounted in Ussing chamber. 
OxA (or OxB, not shown) diluted in saline was added serosally two minutes before 
luminal glucose challenge (10 mmol/l); maximal increase in Isc measured at plateau 
was taken as an index of SGLT-1 activity. B. Non cumulative dose-response curves to 
OxA () or OxB (Z) in reducing glucose-induced Isc. number of tissues studied : 5-7. 
 
Figure 3. Effect of OX1R-antagonist SB334867 on inhibition of glucose-induced Isc 
triggered by OxA or OxB. (A) Non cumulative dose-effect curves for OxA alone ()
or in presence of 5 µmoles/l SB334867 (X) (B) Non cumulative dose-effect curves for 
OxB alone (Z) or in presence of 5 µmoles/l SB334867 (). No significant effect of the 
OX1R antagonist was observed for OxA. By contrast, the antagonist markedly 
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inhibited the inhibitory response induced by OxB at all concentrations. n = 5-7; *, 
P<0.05. 
 
Figure 4. Effect of tetrodotoxin (A, C) and CCK receptor antagonists (B, D) on OxB- 
or OxA-induced inhibition of glucose transport. A: Non-cumulative dose-effect 
curves to OxB alone (Z) or in presence () of tetrodotoxin (TTX, 5 µmoles/l). (B) Dose-
effect curves to OxB alone () or in presence () of CCK2R antagonist YM022 (1 
nmoles/l) plus CCK1R antagonist L-364,718 (1 nmoles/l). (C) Non-cumulative dose-
effect curves to OxA alone () or in presence (X) of TTX; *, P<0.05. (D) Dose-effect 
curves to OxA alone () or in presence () of CCK2R antagonist. Number of tissues 
studied = 5-8 
 
Figure 5. Effect of CCK receptor antagonists on OxA-induced inhibition of glucose 
transport. Inhibitory effect of OxA (10 nmoles/l) was studied in presence of CCK1
receptor antagonist, L-364,718 (1 nmoles/l) or CCK2 receptor antagonist, YM022 (1 
nmoles/l). n=4 - 5 differents tissues. YM022 alone had no effect. *, P<0.05. 
 
Figure 6. Effect of the OX2R agonist Ala11,D-Leu15OxB on inhibition of glucose 
transport. Inhibitory effect of OX2R agonist (10 nmoles/l) was studied alone or in 
presence of TTX (5 µmoles/l) or in the presence of CCK2 receptor antagonist, YM022 
(1 nmoles/l). n= 5-7;  *, P<0.05 vs control. 
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Figure 7. RT-PCR analysis of OxR expression in epithelial and non-epithelial 
fractions of rat jejunal mucosa. OX1R (top panel), OX2R (middle panel) amplicon 
from CHO/OX1R cells and CHO/OX2R (positive controls) are shown in lane 1 and 3, 
respectively. Expression of OX1R transcripts was found only in epithelial cells 
fractions (lane 5), whereas expression of OX2R transcripts was found mainly in non-
epithelial cells (lane 7) with a small positive signal in epithelial cell fraction (lane 5) 
which may be ascribed to the presence of enteroendocrine cells in the epithelial 
fraction. Bottom panel : expression of GADPH transcripts.  Lane 2, 4, 6, 8 : negative 
controls of RT. Lane 9 : negative control of PCR.  
 
Figure 8. Schematic drawing of inhibitory pathways involved in OxA and OxB 
inhibition of glucose absorption by enterocyte. SB334867 : specific antagonist of 
OX1R; TTX : neuronal blocker tetrodotoxin; YM022 : CCK2 receptor antagonist.  
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